SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 15, 2001
CUBIST PHARMACEUTICALS, INC.
-------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-21379 22-3192085
- ---------------------------- --------------- ------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
24 Emily Street, Cambridge, Massachusetts 02139
-----------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (617) 576-1999
--------------
ITEM 5. OTHER EVENTS.
On June 15, 2001, Cubist Pharmaceuticals, Inc. jointly announced the
opening of a new manufacturing facility on a fermentation site of DSM Fine
Chemicals in Capua, Italy dedicated to the commercial production of bulk
daptomycin. The opening of the facility is further described in Cubist's press
release dated June 15, 2001, a copy of which is filed as Exhibit 99.1 to this
Report.
On June 19, 2001, Cubist Pharmaceuticals, Inc. announced the issuance by
the United States Patent and Trademark Office of a patent covering the oral
formulation of ceftriaxone, to which Cubist licensed exclusive rights in
2000. In addition, Cubist announced the achievement of clinically relevant
systemic levels of ceftriaxone delivered directly to the small intestine in
non-human primates and that proof-of-principle studies in man are expected to
begin prior to the end of 2001. The issuance of the patent, the unpublished
ceftriaxone data and the studies are further described in Cubist's press
release dated June 19, 2001, a copy of which is filed as Exhibit 99.2 to this
Report.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(C) EXHIBITS.
Exhibit 99.1 Press Release dated June 15, 2001.
Exhibit 99.2 Press Release dated June 19, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CUBIST PHARMACEUTICALS, INC.
By: /s/ Thomas A. Shea
-------------------------------------
Thomas A. Shea
Vice President Finance and
Administration, Chief Financial
Officer, Treasurer
Dated: June 19, 2001